Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: A clinicopathological and immunohistochemical study of 43 cases

Journal of Urology

Volumn 166, Issue 5, 2001, Pages 1924-1930

  De Pinieux, Gonzague ^b   Flam, Thierry ^b   Zerbib, Marc ^b   Taupin, Pierre ^b   Bellahcène, Akeila ^b   Waltregny, David ^b   Vieillefond, Annick ^b   Poupon, Marie France ^b  

^a INSTITUT CURIE   (France)

^b NONE

Author keywords

Adenocarcinoma; Biological; Bone and bones; Prostate; Prostatic neoplasms; Tumor markers

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; SIALOPROTEIN; THYMIDINE PHOSPHORYLASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION;

EID: 0034789717     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)65722-9     Document Type: Article

References (45)

1. Analysis of bone metastasis of prostatic adenocarcinoma in 137 autopsy cases
2. Pathogenesis of bone metastases: Role of tumor-related proteins
3. Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
4. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development
5. Ectopic expression of bone sialoprotein in human thyroid cancer
6. Expression of bone sialoprotein in human lung cancer
7. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers
8. Vgr-1/BMP-6 induces osteoblastic differentiation of pluripotential mesenchymal cells
9. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia
10. Bone morphogenetic protein-6 expression in normal and malignant prostate
11. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue
12. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies
13. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells
14. Matrix sialoprotein of developing bone
15. Expression of bone sialoprotein (BSP) in developing human tissues
16. Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer
17. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis
18. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers
19. Expression of platelet-derived endothelial cell growth factor in prostatic adenocarcinoma
20. Staging prostate cancer 1997: Current methods and limitations
21. Purification and fragmentation of nondenaturated bone sialoprotein: Evidence for a cryptic RGD-resistant cell attachment domain
22. Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins
23. Cloning of hybridomas producing anti-human thymidine phosphorylase (dThdPase) and establishment ELISA for measuring dThdPase
24. Nonparametric estimation from incomplete observations
25. Evaluation of survival data and two new rank order statistics arising in its consideration
26. The function of the vertebral veins and their role in the spread of metastases. 1940
27. Mechanisms of bone metastasis
28. Why does bone matrix contain non-collagenous proteins? The roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralization and resorption
29. Characterization of native and recombinant bone sialoprotein: Delineation of the mineral-binding and cell adhesion domains and structural analysis of the RGD domain
30. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components
31. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone
32. Mechanisms of the development of osteoblastic metastases
33. Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6
34. Time-dependent expression of bone sialoprotein fragments in osteogenesis induced by bone morphogenetic protein
35. Biosynthesis and in vivo localization of the decapentaplegic-Vg-related protein, DVR-6 (bone morphogenetic protein-6)
36. Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor
37. Evidence that breast cancer associated microcalcifications are mineralized malignant cells
38. Microvessel density in prostate cancer: Prognostic and therapeutic utility
39. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis
40. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: An immunohistochemical study
41. The activity and expression of thymidine phosphorylase in human solid tumors
42. Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas
43. Pharmacology and clinical efficacy of biphoshonates
44. Biphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
45. The potential role of biphosphonates as adjuvant therapy in the prevention of bone metastases